Potential conflict of interest: Dr. Zhu consults for Sanofi-Aventis, Eisai, Exelixis, and Celgene.
Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions
Version of Record online: 26 SEP 2014
© 2014 by the American Association for the Study of Liver Diseases
Volume 60, Issue 5, pages 1776–1782, November 2014
How to Cite
Hato, T., Goyal, L., Greten, T. F., Duda, D. G. and Zhu, A. X. (2014), Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions. Hepatology, 60: 1776–1782. doi: 10.1002/hep.27246
Supported by National Institutes of Health grants P01-CA080124, R01-CA159258, and R21-CA139168, a National Cancer Institute/Proton Beam Federal Share Program award, and the American Cancer Society grant 120733-RSG-11-073-01-TBG (to D.G.D.); and a Postdoctoral Fellowship from Astellas Foundation for Research on Metabolic Disorders, Japan (to T.H.).
- Issue online: 23 OCT 2014
- Version of Record online: 26 SEP 2014
- Accepted manuscript online: 9 JUN 2014 11:07AM EST
- Manuscript Accepted: 31 MAY 2014
- Manuscript Revised: 29 MAY 2014
- Manuscript Received: 15 APR 2014
Additional Supporting Information may be found in the online version of this article at the publisher's website.
Supplemental table 1: Immune checkpoint molecules
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.